JP7824930B2 - 高コレステロール血症の治療方法 - Google Patents

高コレステロール血症の治療方法

Info

Publication number
JP7824930B2
JP7824930B2 JP2023511906A JP2023511906A JP7824930B2 JP 7824930 B2 JP7824930 B2 JP 7824930B2 JP 2023511906 A JP2023511906 A JP 2023511906A JP 2023511906 A JP2023511906 A JP 2023511906A JP 7824930 B2 JP7824930 B2 JP 7824930B2
Authority
JP
Japan
Prior art keywords
compound
formulation
subject
day
cholesterol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023511906A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023538066A5 (https=
JP2023538066A (ja
Inventor
ベラチュー，シベシー
カヒルマクファーランド，エレン
シャオ，チャオフイ
ツァイ，フイ－シン
ウェイ，ルー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen MA Inc filed Critical Biogen MA Inc
Publication of JP2023538066A publication Critical patent/JP2023538066A/ja
Publication of JP2023538066A5 publication Critical patent/JP2023538066A5/ja
Application granted granted Critical
Publication of JP7824930B2 publication Critical patent/JP7824930B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023511906A 2020-08-19 2021-08-19 高コレステロール血症の治療方法 Active JP7824930B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063067786P 2020-08-19 2020-08-19
US63/067,786 2020-08-19
PCT/US2021/046591 WO2022040371A1 (en) 2020-08-19 2021-08-19 Methods for treating hypercholesterolemia

Publications (3)

Publication Number Publication Date
JP2023538066A JP2023538066A (ja) 2023-09-06
JP2023538066A5 JP2023538066A5 (https=) 2024-08-23
JP7824930B2 true JP7824930B2 (ja) 2026-03-05

Family

ID=77693631

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023511906A Active JP7824930B2 (ja) 2020-08-19 2021-08-19 高コレステロール血症の治療方法

Country Status (5)

Country Link
US (1) US12472171B2 (https=)
EP (1) EP4199928B1 (https=)
JP (1) JP7824930B2 (https=)
CN (1) CN116056702B (https=)
WO (1) WO2022040371A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021013807A2 (pt) 2019-01-18 2021-11-30 Astrazeneca Ab Inibidores de pcsk9 e seus métodos de uso
MX2021008661A (es) 2019-01-18 2021-08-19 Astrazeneca Ab Inhibidores de la pcsk9 y metodos de uso de los mismos.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053568A1 (en) 2000-12-28 2002-07-11 Mochida Pharmaceutical Co., Ltd. Cholesterol biosynthesis inhibitors containing as the active ingredient tricyclic spiro compounds
JP2007523858A (ja) 2003-06-24 2007-08-23 ユニバーシティ オブ コネチカット 血管透過性およびアポトーシスの阻害方法
JP2014518541A (ja) 2011-02-07 2014-07-31 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｓ１ｐ調節薬

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6324380B2 (ja) * 2012-07-27 2018-05-16 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｓ１ｐ調節剤および／またはａｔｘ調節剤である化合物
US20230390270A1 (en) * 2020-08-19 2023-12-07 Biogen Ma Inc. Methods for treating remitting multiple sclerosis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053568A1 (en) 2000-12-28 2002-07-11 Mochida Pharmaceutical Co., Ltd. Cholesterol biosynthesis inhibitors containing as the active ingredient tricyclic spiro compounds
JP2007523858A (ja) 2003-06-24 2007-08-23 ユニバーシティ オブ コネチカット 血管透過性およびアポトーシスの阻害方法
JP2014518541A (ja) 2011-02-07 2014-07-31 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｓ１ｐ調節薬

Also Published As

Publication number Publication date
US12472171B2 (en) 2025-11-18
EP4199928A1 (en) 2023-06-28
CN116056702B (zh) 2026-01-23
CN116056702A (zh) 2023-05-02
WO2022040371A1 (en) 2022-02-24
EP4199928B1 (en) 2025-11-26
US20230310405A1 (en) 2023-10-05
JP2023538066A (ja) 2023-09-06

Similar Documents

Publication Publication Date Title
TWI238720B (en) Pharmaceutical composition for use in the treatment of heterozygous familial hypercholesterolemia
EP2310003B1 (en) Inhibitors of carnitin-palmitoyl-transferase-1 for the treatment and prevention of disorders caused by delipidation of neural tissue
JP7824930B2 (ja) 高コレステロール血症の治療方法
EA036404B1 (ru) Фармацевтические композиции для комбинированной терапии
AU2016238886B2 (en) Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders
CA2543596A1 (en) Hdl-boosting combination therapy complexes
US6733793B2 (en) Oral composition with insulin-like activities and methods of use
KR20010093825A (ko) 신규의 핵수용체 리간드
KR102289381B1 (ko) 당뇨치료제 및 고지혈증 치료제를 포함하는 약학적 조성물
CN1367696A (zh) 增强胰岛素作用的方法
US20230390270A1 (en) Methods for treating remitting multiple sclerosis
US6251935B1 (en) Treatment of migraine by administration of α-lipoic acid or derivatives thereof
EP1621210B1 (en) Adiponectin production enhancer
US8501759B2 (en) Use of fibrates
US20250248957A1 (en) Cell differentiation
US12377066B2 (en) Treatment of diseases associated with biliary system destruction
Al-kareem et al. A Comparative Study Between Atorvastatin and Pitavastatin Toxicity on Liver and Kidney in Albino Rats
CN101045076A (zh) 柿叶乙酸乙酯提取物用于预防和/或治疗糖脂代谢相关疾病
CN121177278A (zh) 高车前素在制备降低ldl-c药物中的用途
EP3446689B1 (en) Isothiocyanate compound for use in the treatment of hyperbilirubinemia
KR20170026242A (ko) 간 질환의 예방 또는 치료용 약학적 조성물
Kolisnyk et al. Pharmacological evaluation of sustained release matrix tablets containing Vaccinium myrtillus leaf dry extract as an alpha-glucosidase inhibitory drug
WO2012156970A1 (en) Salvia sclarea seed oil for use in the treatment of cardiovascular diseases or anxiety disorders
Martin Exploring Alternative Therapeutic Interventions For The Treatment Of Leigh Syndrome
MXPA99011665A (en) Pharmaceutical compositions comprising alkanoyl l-carnitine in combination with a statine for treating pathologies brought about by an altered lipid metabolism

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240815

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240815

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250723

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251017

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260130

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260220

R150 Certificate of patent or registration of utility model

Ref document number: 7824930

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150